Ucb

UCB, a pharmaceutical preparation manufacturing company headquartered in Belgium, reported total emissions of approximately 871.6 million kg CO2e in 2025. This includes about 22.2 million kg CO2e from Scope 1 emissions, 16.2 million kg CO2e from Scope 2 (location-based), and 849.8 million kg CO2e from Scope 3 emissions. In 2024, their total emissions were about 790.9 million kg CO2e, with Scope 1 at approximately 21.7 million kg CO2e, Scope 2 (location-based) at around 16.3 million kg CO2e, and Scope 3 at about 769.1 million kg CO2e. Looking back to 2023, total emissions were approximately 85.3 million kg CO2e, consisting of about 20.5 million kg CO2e from Scope 1, 1.6 million kg CO2e from Scope 2 (market-based), and 63.2 million kg CO2e from Scope 3.

UCB has several climate commitments. The company aims to achieve net-zero greenhouse gas emissions across its value chain by 2045. Near-term Science Based Targets Initiative (SBTi) validated targets include reducing absolute Scope 1 and 2 GHG emissions by 73% by 2030 from a 2019 base year. Additionally, UCB commits to reduce absolute Scope 3 GHG emissions from fuel- and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, upstream leased assets, and end-of-life treatment of sold products by 48% within the same timeframe (by 2030 from a 2019 base year). UCB also aims for 80% of its suppliers, by emissions covering purchased goods and services, to have science-based targets by 2028. Long-term SBTi targets include a 90% reduction in absolute Scope 1, 2, and 3 GHG emissions by 2045 from a 2019 base year. Earlier targets from 2017 included absolute reductions of 35% by 2030 and 70% by 2050 for Scope 1 and 2 GHG emissions from a 2016 baseline.